{"id":346698,"date":"2025-08-25T10:31:47","date_gmt":"2025-08-25T10:31:47","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-acadia-pharmaceuticals\/"},"modified":"2025-08-25T10:31:47","modified_gmt":"2025-08-25T10:31:47","slug":"how-to-buy-acadia-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","title":{"rendered":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-346698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, ad\u0131m ad\u0131m sat\u0131n alma rehberi ve 2025-2030 b\u00fcy\u00fcme projeksiyonlar\u0131 ile ACADIA Pharmaceuticals (ACAD) hisselerine nas\u0131l yat\u0131r\u0131m yapaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, ad\u0131m ad\u0131m sat\u0131n alma rehberi ve 2025-2030 b\u00fcy\u00fcme projeksiyonlar\u0131 ile ACADIA Pharmaceuticals (ACAD) hisselerine nas\u0131l yat\u0131r\u0131m yapaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin."},"intro":"N\u00f6rolojik bozukluklar\u0131n tedavisinde devrim yaratan bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. ACADIA Pharmaceuticals, hastalar\u0131n hayat\u0131n\u0131 de\u011fi\u015ftiren \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle sinirbilim inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. Hisseleri hem heyecan verici b\u00fcy\u00fcme potansiyeli sunuyor hem de t\u0131bbi ilerlemeyi desteklemenin tatminini sa\u011fl\u0131yor\u2014bu yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"N\u00f6rolojik bozukluklar\u0131n tedavisinde devrim yaratan bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. ACADIA Pharmaceuticals, hastalar\u0131n hayat\u0131n\u0131 de\u011fi\u015ftiren \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle sinirbilim inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. Hisseleri hem heyecan verici b\u00fcy\u00fcme potansiyeli sunuyor hem de t\u0131bbi ilerlemeyi desteklemenin tatminini sa\u011fl\u0131yor\u2014bu yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 ACAD Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, ACADIA Pharmaceuticals (ACAD) hisseleri <strong>25,74 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse, 52 haftal\u0131k en y\u00fcksek seviyesi olan 25,88 $'\u0131n hemen alt\u0131nda hareket ederek biyoteknoloji sekt\u00f6r\u00fcnde dikkat \u00e7ekici bir g\u00fc\u00e7 g\u00f6steriyor.<\/p> <p><strong>Takviminize not edin: Kas\u0131m 2025 kritik<\/strong>\u2014ACADIA'n\u0131n bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik g\u00fcncellemeler hisse fiyat\u0131nda b\u00fcy\u00fck hareketlere neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Etkisi Analizi: Haberler ACAD Hissesini Nas\u0131l Hareket Ettiriyor<\/h3> <p>\u00d6nceki kazan\u00e7 raporlar\u0131n\u0131n hisse fiyat\u0131n\u0131 nas\u0131l etkiledi\u011fini g\u00f6stereyim:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>24,50 $<\/td><td><strong>%5,1 Art\u0131\u015f<\/strong> (beklentileri a\u015ft\u0131)<\/td><\/tr> <tr><td>7 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>22,80 $<\/td><td><strong>%7,9 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc rehberlik)<\/td><\/tr> <tr><td>27 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>21,40 $<\/td><td><strong>%6,5 Art\u0131\u015f<\/strong> (gelir art\u0131\u015f\u0131)<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>19,20 $<\/td><td><strong>%11,2 Art\u0131\u015f<\/strong> (DAYBUE lansman ba\u015far\u0131s\u0131)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>17,80 $<\/td><td><strong>%8,4 Art\u0131\u015f<\/strong> (pipeline ilerlemesi)<\/td><\/tr> <tr><td>9 May 2024<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>16,50 $<\/td><td><strong>%7,9 Art\u0131\u015f<\/strong> (NUPLAZID geni\u015flemesi)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: ACAD, kazan\u00e7 sezonu boyunca hisselerini elinde tutan yat\u0131r\u0131mc\u0131lar\u0131 s\u00fcrekli \u00f6d\u00fcllendiriyor. Son alt\u0131 raporda ortalama kazan\u00e7 sonras\u0131 art\u0131\u015f <strong>%7,8<\/strong> oldu. Negatif s\u00fcrprizler nadirdir\u2014bu \u015firket nas\u0131l teslim edece\u011fini biliyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: ACAD Rollercoaster'\u0131<\/h2> <p>ACAD hisseleri son alt\u0131 ayda etkileyici bir <strong>%34 getiri<\/strong> sa\u011flad\u0131. \u0130\u015fte yolculu\u011fun nas\u0131l geli\u015fti\u011fi:<\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Seviyesi<\/th><th>Ana Kataliz\u00f6r<\/th><\/tr> <\/thead> <tbody> <tr><td>\u015eubat 2025<\/td><td>~19,20 $<\/td><td>Tatil sonras\u0131 konsolidasyon<\/td><\/tr> <tr><td>Mart 2025<\/td><td>~20,50 $<\/td><td>Ar-Ge G\u00fcn\u00fc iyimserli\u011fi<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>~21,80 $<\/td><td>1. \u00c7eyrek kazan\u00e7 haz\u0131rl\u0131\u011f\u0131<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>~22,80 $<\/td><td>G\u00fc\u00e7l\u00fc 1. \u00c7eyrek sonu\u00e7lar\u0131<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>~23,50 $<\/td><td>Yaz rallisi ba\u015fl\u0131yor<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>~24,90 $<\/td><td>Kurumsal birikim<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>25,74 $<\/td><td>52 haftal\u0131k en y\u00fcksek seviyeye yakla\u015fma<\/td><\/tr> <\/tbody> <\/table> <p><strong>Neden istikrarl\u0131 t\u0131rman\u0131\u015f?<\/strong> Bu performans\u0131 \u00fc\u00e7 fakt\u00f6r y\u00f6nlendirdi:<\/p> <ul> <li><strong>Gelir art\u0131\u015f\u0131<\/strong>: Y\u0131ll\u0131k %9 art\u0131\u015f<\/li> <li><strong>Pipeline ilerlemesi<\/strong>: Yedi Faz 2\/3 denemesi ilerliyor<\/li> <li><strong>Piyasa g\u00fcveni<\/strong>: Analistler hedefleri s\u00fcrekli y\u00fckseltiyor<\/li> <\/ul> <p>Hisse, son 30 g\u00fcnde <strong>19 ye\u015fil g\u00fcn<\/strong> (y\u00fczde 63 pozitif) g\u00f6sterdi ve ortalama g\u00fcnl\u00fck volatilite <strong>%3,29<\/strong>\u2014\u00e7o\u011fu yat\u0131r\u0131mc\u0131 i\u00e7in y\u00f6netilebilir seviyede.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve pipeline potansiyeline dayanarak, gelecekte neler olabilece\u011fi:<\/p> <p><strong>2025 Tahmini<\/strong>: Ortalama hedef 36,22 $ (<strong>%43 yukar\u0131 potansiyel<\/strong>)<br> - Aral\u0131k 2025 hedefi: 38,60 $<br> - Aral\u0131k aral\u0131\u011f\u0131: 21,80 $ - 50,65 $<\/p> <p><strong>2026 Projeksiyonu<\/strong>: 28-42 $ aral\u0131\u011f\u0131<br> - Ana kataliz\u00f6r: PWS Faz 3 sonu\u00e7lar\u0131 ve olas\u0131 FDA ba\u015fvurusu<br> - Uluslararas\u0131 geni\u015fleme b\u00fcy\u00fcmeyi destekliyor<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Tahmini 45-65 $ aral\u0131\u011f\u0131<br> - Piyasada birden fazla \u00fcr\u00fcn<br> - Geni\u015flemi\u015f k\u00fcresel varl\u0131k<br> - Mevcut ila\u00e7lar i\u00e7in potansiyel yeni endikasyonlar<\/p> <p><strong>2030 Vizyonu<\/strong>: Potansiyel 60-90 $ aral\u0131\u011f\u0131<br> - Olgun \u00fcr\u00fcn portf\u00f6y\u00fc<br> - S\u00fcrd\u00fcr\u00fclebilir gelir ak\u0131\u015flar\u0131<br> - Olas\u0131 sat\u0131n alma hedefi<\/p> <p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>G\u00dc\u00c7L\u00dc AL<\/strong>. Risk-getiri oran\u0131 mevcut seviyelerde birikimi destekliyor.<\/p> <h2>\u26a0\ufe0f Riskleri Anlamak: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <p>Yat\u0131r\u0131m yapmadan \u00f6nce bu potansiyel riskleri bilin:<\/p> <p><strong>Klinik Deneme Riski<\/strong> (<a href=\"https:\/\/coincodex.com\/stock\/ACAD\/price-prediction\/\">Klinik Uygulama<\/a>)<br> Hissenin k\u0131sa vadeli kaderi, Prader-Willi sendromu i\u00e7in ACP-101'in ba\u015far\u0131l\u0131 Faz 3 sonu\u00e7lar\u0131na ba\u011fl\u0131. Ba\u015far\u0131s\u0131z denemeler fiyat\u0131 %30-50 d\u00fc\u015f\u00fcrebilir.<\/p> <p><strong>Reg\u00fclasyon Engelleri<\/strong><br> FDA onaylar\u0131 asla garanti de\u011fildir. Gecikmeler veya reddedilmeler gelir projeksiyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir.<\/p> <p><strong>Rekabetin Artmas\u0131<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-high-conviction-buy-pipeline-catalysts-earnings-momentum-2508\/\">Piyasa Bask\u0131s\u0131<\/a>)<br> N\u00f6rolojik tedavilerde yeni oyuncular, NUPLAZID ve DAYBUE'nun pazar pay\u0131n\u0131 azaltabilir.<\/p> <p><strong>Patent Endi\u015feleri<\/strong><br> Patentler 2030 sonras\u0131na kadar uzasa da, jenerik rekabet t\u00fcm ila\u00e7 pazarlar\u0131nda sonunda ortaya \u00e7\u0131kar.<\/p> <h2>\ud83d\udea6 Ye\u015fil I\u015f\u0131klar: ACAD Neden Y\u00fckselebilir<\/h2> <p>\u015eimdi heyecan verici k\u0131s\u0131m\u2014b\u00fcy\u00fck kazan\u00e7lar\u0131 tetikleyebilecek fakt\u00f6rler:<\/p> <p><strong>Pipeline Kataliz\u00f6rleri<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-leveraging-commercial-momentum-robust-pipeline-sustained-growth-2025-2508\/\">B\u00fcy\u00fcme S\u00fcr\u00fcc\u00fcleri<\/a>)<br> 2025 sonuna kadar beklenen be\u015f Faz 2\/3 sonu\u00e7lar\u0131, birden fazla f\u0131rsat yarat\u0131yor.<\/p> <p><strong>Mali G\u00fc\u00e7<\/strong><br> 762 milyon $ nakit rezervi, denemeler ve geni\u015fleme i\u00e7in seyir alan\u0131 sa\u011fl\u0131yor, sermaye art\u0131r\u0131m\u0131 olmadan.<\/p> <p><strong>Pazar Geni\u015flemesi<\/strong><br> Trofinetide i\u00e7in Japonya lansman\u0131 ve 2026'da EMA onay\u0131, devasa yeni pazarlar a\u00e7\u0131yor.<\/p> <p><strong>Gelir \u00c7e\u015fitlendirmesi<\/strong> (<a href=\"https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-reports-second-quarter-2025-financial\/\">2. \u00c7eyrek Performans\u0131<\/a>)<br> NUPLAZID (%7 Y\u0131ll\u0131k Art\u0131\u015f) ve DAYBUE, istikrarl\u0131 \u00e7ift \u00fcr\u00fcn gelir ak\u0131\u015flar\u0131 yarat\u0131yor.<\/p> <h2>\ud83d\udcf0 Son Haberlerin Etkisi: T\u00fcccar Perspektifi<\/h2> <p>ACADIA'n\u0131n 2025 2. \u00e7eyrek sonu\u00e7lar\u0131 t\u00fcccarlar i\u00e7in birka\u00e7 \u00f6nemli \u00e7\u0131kar\u0131m sundu:<\/p> <p><strong>Gelir Beklentiyi A\u015ft\u0131<\/strong>: 264,6M $ vs. beklenen 260M $\u2014bu, <strong>%1,8 s\u00fcrprizi<\/strong> fiyat\u0131 hareketlendirdi.<\/p> <p><strong>Rehberlik Y\u00fckseltildi<\/strong>: Y\u0131ll\u0131k gelir rehberli\u011fi 1,045-1,095 milyar $ olarak art\u0131r\u0131ld\u0131, y\u00f6netim g\u00fcvenini g\u00f6steriyor.<\/p> <p><strong>Ar-Ge H\u0131z\u0131<\/strong>: Yedi Faz 2\/3 \u00e7al\u0131\u015fma ba\u015flat\u0131lmas\u0131 planlan\u0131yor, g\u00fc\u00e7l\u00fc pipeline geli\u015fimi sinyali.<\/p> <p><strong>Pratik \u00e7\u0131kar\u0131m<\/strong>: Kazan\u00e7 sezonu, \u00f6ng\u00f6r\u00fclebilir volatilite desenleri yarat\u0131r\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in ideal.<\/p> <h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <p>Analizime dayanarak, \u00f6nerilerim \u015funlar:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fc ile ba\u015flayarak suyu test edin<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: Kazan\u00e7 tarihleri civar\u0131nda 2-3 ay i\u00e7inde par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Uyar\u0131lar kurun<\/strong>: Daha iyi giri\u015f i\u00e7in 24,50 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015fleri takip edin<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu bir 2-3 y\u0131ll\u0131k hikaye, haftal\u0131k i\u015flem de\u011fil<\/li> <\/ol> <p><strong>Esprili deneyimli tavsiye<\/strong>: \"Biyotek hisse senetleriyle i\u015flem yapmak fl\u00f6rt etmek gibidir\u2014bazen \u00e7\u0131\u011f\u0131r a\u00e7an terapiyi bulursunuz, bazen yan etkileri. Ba\u011flanmadan \u00f6nce etiketi mutlaka okuyun!\"<\/p> <h2>\u2705 ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <p>Haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte eylem plan\u0131n\u0131z:<\/p> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu se\u00e7in<\/td><td>NASDAQ hisseleri ve rekabet\u00e7i \u00fccretler sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Do\u011frulamay\u0131 tamamlay\u0131n<\/td><td>Hisse i\u015flemleri i\u00e7in KYC gereklidir<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"ACAD\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit emri belirleyin<\/td><td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonu izleyin<\/td><td>Performans\u0131 takip edin ama duygusal kararlar vermeyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 ACAD Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2> <p>Kademeli pozisyon olu\u015fturmak isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito<\/strong>: Sadece 5 $ ile ACAD pozisyonunuzu a\u015f\u0131r\u0131 y\u00fcklenmeden olu\u015fturmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci ve herhangi bir resmi kimlik ile h\u0131zl\u0131 i\u015flem<\/li> <li><strong>Esnek para \u00e7ekme<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla se\u00e7enek<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong>: ACAD gibi y\u00fcksek fiyatl\u0131 hisselerde zamanla pozisyon olu\u015fturmak i\u00e7in ideal<\/li> <\/ul> <h2>\ud83e\udde0 ACADIA Pharmaceuticals: 2025 \u015eirket Profili<\/h2> <p>ACADIA sadece ba\u015fka bir biyotek hisse senedi de\u011fil\u2014n\u00f6rolojik tedavilerde \u00f6nc\u00fcler ve hastalar\u0131n hayat\u0131n\u0131 de\u011fi\u015ftiren iki ticari \u00fcr\u00fcnle:<\/p> <p><strong>Ne yap\u0131yorlar<\/strong>: Merkezi sinir sistemi bozukluklar\u0131 i\u00e7in yenilik\u00e7i tedaviler geli\u015ftirip ticarile\u015ftiriyorlar<\/p> <p><strong>Amiral gemisi \u00fcr\u00fcnler<\/strong>:<br> - NUPLAZID\u00ae: Parkinson hastal\u0131\u011f\u0131 psikozu i\u00e7in ilk ve tek FDA onayl\u0131 tedavi<br> - DAYBUE\u2122: Rett sendromu i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedavi<\/p> <p><strong>Pazar konumu<\/strong>: 4,34 milyar $ piyasa de\u011feri ve 700+ \u00e7al\u0131\u015fanla inovasyonu s\u00fcrd\u00fcr\u00fcyorlar<\/p> <p><strong>2025 ilgin\u00e7 ger\u00e7ek<\/strong>: ACADIA'n\u0131n Ar-Ge ekibi <strong>yedi e\u015f zamanl\u0131 Faz 2\/3 denemesi<\/strong> \u00fczerinde \u00e7al\u0131\u015f\u0131yor\u2014bu, \u00e7oklu n\u00f6rolojik durumlarda kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 ele alma taahh\u00fcd\u00fcn\u00fc g\u00f6steren son derece agresif bir pipeline geni\u015flemesi.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 ACAD Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, ACADIA Pharmaceuticals (ACAD) hisseleri <strong>25,74 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse, 52 haftal\u0131k en y\u00fcksek seviyesi olan 25,88 $&#8217;\u0131n hemen alt\u0131nda hareket ederek biyoteknoloji sekt\u00f6r\u00fcnde dikkat \u00e7ekici bir g\u00fc\u00e7 g\u00f6steriyor.<\/p>\n<p><strong>Takviminize not edin: Kas\u0131m 2025 kritik<\/strong>\u2014ACADIA&#8217;n\u0131n bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik g\u00fcncellemeler hisse fiyat\u0131nda b\u00fcy\u00fck hareketlere neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Etkisi Analizi: Haberler ACAD Hissesini Nas\u0131l Hareket Ettiriyor<\/h3>\n<p>\u00d6nceki kazan\u00e7 raporlar\u0131n\u0131n hisse fiyat\u0131n\u0131 nas\u0131l etkiledi\u011fini g\u00f6stereyim:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>24,50 $<\/td>\n<td><strong>%5,1 Art\u0131\u015f<\/strong> (beklentileri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>22,80 $<\/td>\n<td><strong>%7,9 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc rehberlik)<\/td>\n<\/tr>\n<tr>\n<td>27 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>21,40 $<\/td>\n<td><strong>%6,5 Art\u0131\u015f<\/strong> (gelir art\u0131\u015f\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>19,20 $<\/td>\n<td><strong>%11,2 Art\u0131\u015f<\/strong> (DAYBUE lansman ba\u015far\u0131s\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>17,80 $<\/td>\n<td><strong>%8,4 Art\u0131\u015f<\/strong> (pipeline ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>16,50 $<\/td>\n<td><strong>%7,9 Art\u0131\u015f<\/strong> (NUPLAZID geni\u015flemesi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: ACAD, kazan\u00e7 sezonu boyunca hisselerini elinde tutan yat\u0131r\u0131mc\u0131lar\u0131 s\u00fcrekli \u00f6d\u00fcllendiriyor. Son alt\u0131 raporda ortalama kazan\u00e7 sonras\u0131 art\u0131\u015f <strong>%7,8<\/strong> oldu. Negatif s\u00fcrprizler nadirdir\u2014bu \u015firket nas\u0131l teslim edece\u011fini biliyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: ACAD Rollercoaster&#8217;\u0131<\/h2>\n<p>ACAD hisseleri son alt\u0131 ayda etkileyici bir <strong>%34 getiri<\/strong> sa\u011flad\u0131. \u0130\u015fte yolculu\u011fun nas\u0131l geli\u015fti\u011fi:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Seviyesi<\/th>\n<th>Ana Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u015eubat 2025<\/td>\n<td>~19,20 $<\/td>\n<td>Tatil sonras\u0131 konsolidasyon<\/td>\n<\/tr>\n<tr>\n<td>Mart 2025<\/td>\n<td>~20,50 $<\/td>\n<td>Ar-Ge G\u00fcn\u00fc iyimserli\u011fi<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>~21,80 $<\/td>\n<td>1. \u00c7eyrek kazan\u00e7 haz\u0131rl\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>~22,80 $<\/td>\n<td>G\u00fc\u00e7l\u00fc 1. \u00c7eyrek sonu\u00e7lar\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>~23,50 $<\/td>\n<td>Yaz rallisi ba\u015fl\u0131yor<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>~24,90 $<\/td>\n<td>Kurumsal birikim<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>25,74 $<\/td>\n<td>52 haftal\u0131k en y\u00fcksek seviyeye yakla\u015fma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Neden istikrarl\u0131 t\u0131rman\u0131\u015f?<\/strong> Bu performans\u0131 \u00fc\u00e7 fakt\u00f6r y\u00f6nlendirdi:<\/p>\n<ul>\n<li><strong>Gelir art\u0131\u015f\u0131<\/strong>: Y\u0131ll\u0131k %9 art\u0131\u015f<\/li>\n<li><strong>Pipeline ilerlemesi<\/strong>: Yedi Faz 2\/3 denemesi ilerliyor<\/li>\n<li><strong>Piyasa g\u00fcveni<\/strong>: Analistler hedefleri s\u00fcrekli y\u00fckseltiyor<\/li>\n<\/ul>\n<p>Hisse, son 30 g\u00fcnde <strong>19 ye\u015fil g\u00fcn<\/strong> (y\u00fczde 63 pozitif) g\u00f6sterdi ve ortalama g\u00fcnl\u00fck volatilite <strong>%3,29<\/strong>\u2014\u00e7o\u011fu yat\u0131r\u0131mc\u0131 i\u00e7in y\u00f6netilebilir seviyede.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve pipeline potansiyeline dayanarak, gelecekte neler olabilece\u011fi:<\/p>\n<p><strong>2025 Tahmini<\/strong>: Ortalama hedef 36,22 $ (<strong>%43 yukar\u0131 potansiyel<\/strong>)<br \/> &#8211; Aral\u0131k 2025 hedefi: 38,60 $<br \/> &#8211; Aral\u0131k aral\u0131\u011f\u0131: 21,80 $ &#8211; 50,65 $<\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 28-42 $ aral\u0131\u011f\u0131<br \/> &#8211; Ana kataliz\u00f6r: PWS Faz 3 sonu\u00e7lar\u0131 ve olas\u0131 FDA ba\u015fvurusu<br \/> &#8211; Uluslararas\u0131 geni\u015fleme b\u00fcy\u00fcmeyi destekliyor<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Tahmini 45-65 $ aral\u0131\u011f\u0131<br \/> &#8211; Piyasada birden fazla \u00fcr\u00fcn<br \/> &#8211; Geni\u015flemi\u015f k\u00fcresel varl\u0131k<br \/> &#8211; Mevcut ila\u00e7lar i\u00e7in potansiyel yeni endikasyonlar<\/p>\n<p><strong>2030 Vizyonu<\/strong>: Potansiyel 60-90 $ aral\u0131\u011f\u0131<br \/> &#8211; Olgun \u00fcr\u00fcn portf\u00f6y\u00fc<br \/> &#8211; S\u00fcrd\u00fcr\u00fclebilir gelir ak\u0131\u015flar\u0131<br \/> &#8211; Olas\u0131 sat\u0131n alma hedefi<\/p>\n<p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in <strong>G\u00dc\u00c7L\u00dc AL<\/strong>. Risk-getiri oran\u0131 mevcut seviyelerde birikimi destekliyor.<\/p>\n<h2>\u26a0\ufe0f Riskleri Anlamak: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<p>Yat\u0131r\u0131m yapmadan \u00f6nce bu potansiyel riskleri bilin:<\/p>\n<p><strong>Klinik Deneme Riski<\/strong> (<a href=\"https:\/\/coincodex.com\/stock\/ACAD\/price-prediction\/\">Klinik Uygulama<\/a>)<br \/> Hissenin k\u0131sa vadeli kaderi, Prader-Willi sendromu i\u00e7in ACP-101&#8217;in ba\u015far\u0131l\u0131 Faz 3 sonu\u00e7lar\u0131na ba\u011fl\u0131. Ba\u015far\u0131s\u0131z denemeler fiyat\u0131 %30-50 d\u00fc\u015f\u00fcrebilir.<\/p>\n<p><strong>Reg\u00fclasyon Engelleri<\/strong><br \/> FDA onaylar\u0131 asla garanti de\u011fildir. Gecikmeler veya reddedilmeler gelir projeksiyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir.<\/p>\n<p><strong>Rekabetin Artmas\u0131<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-high-conviction-buy-pipeline-catalysts-earnings-momentum-2508\/\">Piyasa Bask\u0131s\u0131<\/a>)<br \/> N\u00f6rolojik tedavilerde yeni oyuncular, NUPLAZID ve DAYBUE&#8217;nun pazar pay\u0131n\u0131 azaltabilir.<\/p>\n<p><strong>Patent Endi\u015feleri<\/strong><br \/> Patentler 2030 sonras\u0131na kadar uzasa da, jenerik rekabet t\u00fcm ila\u00e7 pazarlar\u0131nda sonunda ortaya \u00e7\u0131kar.<\/p>\n<h2>\ud83d\udea6 Ye\u015fil I\u015f\u0131klar: ACAD Neden Y\u00fckselebilir<\/h2>\n<p>\u015eimdi heyecan verici k\u0131s\u0131m\u2014b\u00fcy\u00fck kazan\u00e7lar\u0131 tetikleyebilecek fakt\u00f6rler:<\/p>\n<p><strong>Pipeline Kataliz\u00f6rleri<\/strong> (<a href=\"https:\/\/www.ainvest.com\/news\/acadia-pharmaceuticals-leveraging-commercial-momentum-robust-pipeline-sustained-growth-2025-2508\/\">B\u00fcy\u00fcme S\u00fcr\u00fcc\u00fcleri<\/a>)<br \/> 2025 sonuna kadar beklenen be\u015f Faz 2\/3 sonu\u00e7lar\u0131, birden fazla f\u0131rsat yarat\u0131yor.<\/p>\n<p><strong>Mali G\u00fc\u00e7<\/strong><br \/> 762 milyon $ nakit rezervi, denemeler ve geni\u015fleme i\u00e7in seyir alan\u0131 sa\u011fl\u0131yor, sermaye art\u0131r\u0131m\u0131 olmadan.<\/p>\n<p><strong>Pazar Geni\u015flemesi<\/strong><br \/> Trofinetide i\u00e7in Japonya lansman\u0131 ve 2026&#8217;da EMA onay\u0131, devasa yeni pazarlar a\u00e7\u0131yor.<\/p>\n<p><strong>Gelir \u00c7e\u015fitlendirmesi<\/strong> (<a href=\"https:\/\/acadia.com\/en-us\/media\/news-releases\/acadia-pharmaceuticals-reports-second-quarter-2025-financial\/\">2. \u00c7eyrek Performans\u0131<\/a>)<br \/> NUPLAZID (%7 Y\u0131ll\u0131k Art\u0131\u015f) ve DAYBUE, istikrarl\u0131 \u00e7ift \u00fcr\u00fcn gelir ak\u0131\u015flar\u0131 yarat\u0131yor.<\/p>\n<h2>\ud83d\udcf0 Son Haberlerin Etkisi: T\u00fcccar Perspektifi<\/h2>\n<p>ACADIA&#8217;n\u0131n 2025 2. \u00e7eyrek sonu\u00e7lar\u0131 t\u00fcccarlar i\u00e7in birka\u00e7 \u00f6nemli \u00e7\u0131kar\u0131m sundu:<\/p>\n<p><strong>Gelir Beklentiyi A\u015ft\u0131<\/strong>: 264,6M $ vs. beklenen 260M $\u2014bu, <strong>%1,8 s\u00fcrprizi<\/strong> fiyat\u0131 hareketlendirdi.<\/p>\n<p><strong>Rehberlik Y\u00fckseltildi<\/strong>: Y\u0131ll\u0131k gelir rehberli\u011fi 1,045-1,095 milyar $ olarak art\u0131r\u0131ld\u0131, y\u00f6netim g\u00fcvenini g\u00f6steriyor.<\/p>\n<p><strong>Ar-Ge H\u0131z\u0131<\/strong>: Yedi Faz 2\/3 \u00e7al\u0131\u015fma ba\u015flat\u0131lmas\u0131 planlan\u0131yor, g\u00fc\u00e7l\u00fc pipeline geli\u015fimi sinyali.<\/p>\n<p><strong>Pratik \u00e7\u0131kar\u0131m<\/strong>: Kazan\u00e7 sezonu, \u00f6ng\u00f6r\u00fclebilir volatilite desenleri yarat\u0131r\u2014stratejik giri\u015f noktalar\u0131 i\u00e7in ideal.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<p>Analizime dayanarak, \u00f6nerilerim \u015funlar:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fc ile ba\u015flayarak suyu test edin<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: Kazan\u00e7 tarihleri civar\u0131nda 2-3 ay i\u00e7inde par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Uyar\u0131lar kurun<\/strong>: Daha iyi giri\u015f i\u00e7in 24,50 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015fleri takip edin<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu bir 2-3 y\u0131ll\u0131k hikaye, haftal\u0131k i\u015flem de\u011fil<\/li>\n<\/ol>\n<p><strong>Esprili deneyimli tavsiye<\/strong>: &#8220;Biyotek hisse senetleriyle i\u015flem yapmak fl\u00f6rt etmek gibidir\u2014bazen \u00e7\u0131\u011f\u0131r a\u00e7an terapiyi bulursunuz, bazen yan etkileri. Ba\u011flanmadan \u00f6nce etiketi mutlaka okuyun!&#8221;<\/p>\n<h2>\u2705 ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<p>Haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte eylem plan\u0131n\u0131z:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu se\u00e7in<\/td>\n<td>NASDAQ hisseleri ve rekabet\u00e7i \u00fccretler sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Do\u011frulamay\u0131 tamamlay\u0131n<\/td>\n<td>Hisse i\u015flemleri i\u00e7in KYC gereklidir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;ACAD&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit emri belirleyin<\/td>\n<td>Piyasa emirlerinden ka\u00e7\u0131n\u0131n\u2014maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Performans\u0131 takip edin ama duygusal kararlar vermeyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 ACAD Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2>\n<p>Kademeli pozisyon olu\u015fturmak isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito<\/strong>: Sadece 5 $ ile ACAD pozisyonunuzu a\u015f\u0131r\u0131 y\u00fcklenmeden olu\u015fturmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci ve herhangi bir resmi kimlik ile h\u0131zl\u0131 i\u015flem<\/li>\n<li><strong>Esnek para \u00e7ekme<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla se\u00e7enek<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong>: ACAD gibi y\u00fcksek fiyatl\u0131 hisselerde zamanla pozisyon olu\u015fturmak i\u00e7in ideal<\/li>\n<\/ul>\n<h2>\ud83e\udde0 ACADIA Pharmaceuticals: 2025 \u015eirket Profili<\/h2>\n<p>ACADIA sadece ba\u015fka bir biyotek hisse senedi de\u011fil\u2014n\u00f6rolojik tedavilerde \u00f6nc\u00fcler ve hastalar\u0131n hayat\u0131n\u0131 de\u011fi\u015ftiren iki ticari \u00fcr\u00fcnle:<\/p>\n<p><strong>Ne yap\u0131yorlar<\/strong>: Merkezi sinir sistemi bozukluklar\u0131 i\u00e7in yenilik\u00e7i tedaviler geli\u015ftirip ticarile\u015ftiriyorlar<\/p>\n<p><strong>Amiral gemisi \u00fcr\u00fcnler<\/strong>:<br \/> &#8211; NUPLAZID\u00ae: Parkinson hastal\u0131\u011f\u0131 psikozu i\u00e7in ilk ve tek FDA onayl\u0131 tedavi<br \/> &#8211; DAYBUE\u2122: Rett sendromu i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedavi<\/p>\n<p><strong>Pazar konumu<\/strong>: 4,34 milyar $ piyasa de\u011feri ve 700+ \u00e7al\u0131\u015fanla inovasyonu s\u00fcrd\u00fcr\u00fcyorlar<\/p>\n<p><strong>2025 ilgin\u00e7 ger\u00e7ek<\/strong>: ACADIA&#8217;n\u0131n Ar-Ge ekibi <strong>yedi e\u015f zamanl\u0131 Faz 2\/3 denemesi<\/strong> \u00fczerinde \u00e7al\u0131\u015f\u0131yor\u2014bu, \u00e7oklu n\u00f6rolojik durumlarda kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 ele alma taahh\u00fcd\u00fcn\u00fc g\u00f6steren son derece agresif bir pipeline geni\u015flemesi.<\/p>\n"},"faq":[{"question":"ACADIA Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"ACADIA Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"ACAD hissesinin gelecekteki fiyat beklentisi nedir?","answer":"Analist projeksiyonlar\u0131na g\u00f6re 2025 i\u00e7in ortalama hedef fiyat 36,22 $ olup, bu mevcut fiyat\u0131n %43 \u00fczerinde bir potansiyel g\u00f6stermektedir."},{"question":"ACADIA Pharmaceuticals'\u0131n ana \u00fcr\u00fcnleri nelerdir?","answer":"\u015eirketin amiral gemisi \u00fcr\u00fcnleri NUPLAZID\u00ae (Parkinson hastal\u0131\u011f\u0131 psikozu i\u00e7in) ve DAYBUE\u2122 (Rett sendromu i\u00e7in) tedavileridir."},{"question":"ACAD hissesine yat\u0131r\u0131m yaparken hangi riskler vard\u0131r?","answer":"Ba\u015far\u0131s\u0131z klinik denemeler, reg\u00fclasyon gecikmeleri, artan rekabet ve patent s\u00fcresi dolmas\u0131 gibi riskler yat\u0131r\u0131mc\u0131lar\u0131n dikkat etmesi gereken \u00f6nemli fakt\u00f6rlerdir."},{"question":"ACADIA Pharmaceuticals'\u0131n Ar-Ge \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda ne biliyoruz?","answer":"\u015eirket 2025 y\u0131l\u0131nda yedi e\u015f zamanl\u0131 Faz 2\/3 klinik denemesi y\u00fcr\u00fctmekte olup, bu da agresif bir pipeline geni\u015flemesini ve yenilik\u00e7i tedavi geli\u015ftirme taahh\u00fcd\u00fcn\u00fc g\u00f6stermektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"ACADIA Pharmaceuticals hisseleri nereden al\u0131n\u0131r?","answer":"ACADIA Pharmaceuticals hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"ACAD hissesinin gelecekteki fiyat beklentisi nedir?","answer":"Analist projeksiyonlar\u0131na g\u00f6re 2025 i\u00e7in ortalama hedef fiyat 36,22 $ olup, bu mevcut fiyat\u0131n %43 \u00fczerinde bir potansiyel g\u00f6stermektedir."},{"question":"ACADIA Pharmaceuticals'\u0131n ana \u00fcr\u00fcnleri nelerdir?","answer":"\u015eirketin amiral gemisi \u00fcr\u00fcnleri NUPLAZID\u00ae (Parkinson hastal\u0131\u011f\u0131 psikozu i\u00e7in) ve DAYBUE\u2122 (Rett sendromu i\u00e7in) tedavileridir."},{"question":"ACAD hissesine yat\u0131r\u0131m yaparken hangi riskler vard\u0131r?","answer":"Ba\u015far\u0131s\u0131z klinik denemeler, reg\u00fclasyon gecikmeleri, artan rekabet ve patent s\u00fcresi dolmas\u0131 gibi riskler yat\u0131r\u0131mc\u0131lar\u0131n dikkat etmesi gereken \u00f6nemli fakt\u00f6rlerdir."},{"question":"ACADIA Pharmaceuticals'\u0131n Ar-Ge \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda ne biliyoruz?","answer":"\u015eirket 2025 y\u0131l\u0131nda yedi e\u015f zamanl\u0131 Faz 2\/3 klinik denemesi y\u00fcr\u00fctmekte olup, bu da agresif bir pipeline geni\u015flemesini ve yenilik\u00e7i tedavi geli\u015ftirme taahh\u00fcd\u00fcn\u00fc g\u00f6stermektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T10:31:47+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T10:31:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\",\"name\":\"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"datePublished\":\"2025-08-25T10:31:47+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T10:31:47+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T10:31:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/","name":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r - ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","datePublished":"2025-08-25T10:31:47+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"ACADIA Pharmaceuticals Inc. (ACAD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; ACADIA Pharmaceuticals Inc. (ACAD) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":346700,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu ACADIA Pharmaceuticals Inc. (ACAD) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":346696,"slug":"how-to-buy-acadia-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da ACADIA Pharmaceuticals Inc. (ACAD) - Investimento em a\u00e7\u00f5es da ACADIA Pharmaceuticals Inc. (ACAD)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-acadia-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/346698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=346698"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/346698\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334045"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=346698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=346698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=346698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}